Supplementary Materials
Figure 1: Kaplan-Meier survival curve for grade II and III resected STS in the Netherlands between 2000 and 2017
Figure 2: Kaplan-Meier survival curves for grade II and III resected STS in the Netherlands between 2000 and 2017, by equally sized age groups
Table 1: OS at 1, 2, 5 and 10 years along with 95% confidence interval for grade II and III resected STS in the Netherlands between 2000 and 2017, by equally sized age groups
Equally sized age groups
81.4% (79.4-83.4)
66.8% (64.4-69.2)
42.0% (39.5-44.5)
19.8% (17.3-22.3)
p<0.001
Figure 3: Kaplan-Meier survival curves for grade II and III resected STS in the Netherlands between 2000 and 2017, by sex
Table 2: OS at 1, 2, 5 and 10 years along with 95% confidence interval for grade II and III resected STS in the Netherlands between 2000 and 2017, by sex
Sex
89.0% (87.6-90.4)
77.3% (75.5-79.1)
58.6% (56.4-60.8)
46.1% (43.7-48.5)
p=0.932
Figure 4: Kaplan-Meier survival curves for grade II and III resected STS in the Netherlands between 2000 and 2017, by year of diagnosis
Table 3: OS at 1, 2, 5 and 10 years along with 95% confidence interval for grade II and III resected STS in the Netherlands between 2000 and 2017, by year of diagnosis
Year of diagnosis
1 year OS
2 year OS
5 year OS
10 year OS
2000-2008 (N=2254)
90.3% (89.1-91.5)
79.0% (77.4-80.6)
60.6% (58.6-62.6)
45.1% (42.2-48.0)
p=0.122
Figure 5: Kaplan-Meier survival curves for grade II and III resected STS in the Netherlands between 2000 and 2017, by histological subtype
Table 4: OS at 1, 2, 5 and 10 years along with 95% confidence interval for grade II and III resected STS in the Netherlands between 2000 and 2017, by histological subtype
Subtype
86.8% (84.4-89.2)
74.0% (71.1-76.9)
60.8% (57.3-64.3)
49.1% (45.0-53.2)
P<0.001
Figure 6: Kaplan-Meier survival curves for grade II and III resected STS in the Netherlands between 2000 and 2017, by tumor location
Table 5: OS at 1, 2, 5 and 10 years along with 95% confidence interval for grade II and III resected STS in the Netherlands between 2000 and 2017, by tumor location
Tumor location
66.8% (52.1-81.5)
46.2% (30.5-61.9)
32.8% (16.9-48.7)
15.6% (0.0-31.9)
P<0.001
Figure 7: Kaplan-Meier survival curves for grade II and III resected STS in the Netherlands between 2000 and 2017, by grade
Table 6: OS at 1, 2, 5 and 10 years along with 95% confidence interval for grade II and III resected STS in the Netherlands between 2000 and 2017, by grade
Tumor grade
87.4% (86.2-88.6)
74.8% (73.2-76.4)
54.9% (53.1-56.7)
42.6% (40.6-44.6)
p<0.001
Figure 8: Kaplan-Meier survival curves for grade II and III resected STS in the Netherlands between 2000 and 2017, by tumor size
Table 7: OS at 1, 2, 5 and 10 years along with 95% confidence interval for grade II and III resected STS in the Netherlands between 2000 and 2017, by tumor size
Tumor size
86.6% (85.2-88.0)
73.7% (71.9-75.5)
53.4% (51.2-55.6)
41.3% (38.9-43.7)
p<0.001
Figure 9: Kaplan-Meier survival curves for grade II and III resected STS in the Netherlands between 2000 and 2017, by tumor depth
Table 8: OS at 1, 2, 5 and 10 years along with 95% confidence interval for grade II and III resected STS in the Netherlands between 2000 and 2017, by tumor depth
Tumor depth
86.8% (85.2-88.4)
74.6% (72.4-76.8)
54.8% (52.3-57.3)
42.2% (39.7-44.7)
p<0.001
Figure 10: Kaplan-Meier survival curves for grade II and III resected STS in the Netherlands between 2000 and 2017, by radicality of the surgery
Table 9: OS at 1, 2, 5 and 10 years along with 95% confidence interval for grade II and III resected STS in the Netherlands between 2000 and 2017, by radicality of the surgery
Radicality of the surgery
79.6% (76.7-82.5)
66.4% (62.9-69.9)
45.3% (41.6-49.0)
32.4% (28.5-36.3)
p<0.001
Figure 11: Kaplan-Meier survival curves for grade II and III resected STS in the Netherlands between 2000 and 2017, by peri-operative radiotherapy
Table 10: OS at 1, 2, 5 and 10 years along with 95% confidence interval for grade II and III resected STS in the Netherlands between 2000 and 2017, by peri-operative radiotherapy
Peri-operative radiotherapy
93.0% (92.0-94.0)
82.0% (80.4-83.6)
63.9% (61.9-65.9)
50.3% (48.1-52.5)
p<0.001
Figure 12: Kaplan-Meier survival curves for grade II and III resected STS in the Netherlands between 2000 and 2017, by peri-operative chemotherapy
Table 11: OS at 1, 2, 5 and 10 years along with 95% confidence interval for grade II and III resected STS in the Netherlands between 2000 and 2017, by peri-operative chemotherapy
Peri-operative chemotherapy
90.3% (86.6-94.0)
72.4% (66.9-77.9)
56.3% (50.0-62.6)
48.6% (41.9-55.3)
p=0.859
Figure 13: Percentage of patients receiving peri-operative chemotherapy per subtype for grade II and III resected STS in the Netherlands between 2000 and 2017
No TT
Post-op TT
Pre-op TT
2000-2002
625
0
0
0
2003-2005
716
0
0
0
2006-2008
789
0
2
1
2009-2011
770
0
2
0
2012-2014
843
0
6
0
2015-2017
942
0
10
1
Table 12: The use of peri-operative targeted therapy for grade II and III resected STS in the Netherlands between 2000 and 2017
UPS 2000-2005 2006-2011 2012-2017 4.2 2.2999999999999998 1.2 Myxofibrosarcoma 2000-2005 2006-2011 2012-2017 6 0.9 0 Leiomyosarcoma 2000-2005 2006-2011 2012-2017 0.9 0.4 1.7 Angiosarcoma 2000-2005 2006-2011 2012-2017 0 4.3 7.8 MPNST 2000-2005 2006-2011 2012-2017 4.9000000000000004 7.3 1.9 Synovial sarcoma 2000-2005 2006-2011 2012-2017 9.4 5.7 7.8 MLS 2000-2005 2006-2011 2012-2017 4.0999999999999996 0 0 Pleomorphic liposarcoma 2000-2005 2006-2011 2012-2017 9.3000000000000007 2.4 2.2999999999999998 Dediff. Liposarcoma 2000-2005 2006-2011 2012-2017 0 2.7 1.7 Liposarcoma NOS 2000-2005 2006-2011 2012-2017 11.6 0 0